The Chinese Communist Party Industrial and Military Espionage Modus Operandi ... Naive and Foolish Canada

"The National Research Council retains the intellectual property related to the cell line, while CanSino, in turn, owns all intellectual property rights for the vaccines it develops."

then-Industry Minister Navdeep Bains, August 

"Under this agreement, CanSino was to provide candidate vaccine doses and transfer their vaccine technology, free of charge, for Phase 1 and 2 clinical trials in Canada, and grant the NRC a non-exclusive right to use, produce, and reproduce the vaccine for emergency pandemic use [NRC in  response to a question in the House of Commons]." 

Question raised by Conservative Health critic Michelle Rempel Garner

The Chinese embassy in Ottawa (Jolson Lim/iPolitics)

 

This, of a contractual agreement signed by the Canadian government with a Chinese pharmaceutical company whose founder and CEO had ties with Canada, having attended university and received his doctorate in Canada, and worked for a large Canadian pharmaceutical company before returning to China and launching his own business, linked to the People's Republic of China's military laboratories. 

This has a familiar ring. Canada's hugely successful communications giant Nortel, employed Chinese IT personnel, some of whom managed to infiltrate its highest echelons of executive management to secure trade secrets which made their way back to China as competitors to Nortel. A scenario that led to the company's demise while Huawei, where many of the former Nortel employees were then employed, began to rise becoming China's premier communications giant.

Infiltration by Chinese nationals who studied in Canada and became employed at Canadian companies securing classified data later transferred to China is not exactly new; industrial and military espionage is an acknowledged Chinese Communist Party specialty. Two years ago at Canada's National Microbiology Laboratory in Winnipeg, Xiangguo Qiu, then head of the vaccine development and antiviral therapies section, along with her husband also employed there, and a Chinese student in microbiology were escorted out of the facility.

They had somehow managed to send to China Canadian formulas not meant to leave the country much less fall into the hands of any entity outside the Microbiology Laboratory in Winnipeg. An investigation was launched by the RCMP after they were removed from their positions for "policy breaches" linked to a laboratory in Wuhan, China known to conduct research into deadly pathogens. The background of the situation and the findings of the investigation were never made public.

Yet despite these sinister and blatant events at purloining trade and industrial secrets from other countries that China is infamous for, the Canadian government under Justin Trudeau chose to sign a contract with another Chinese company for the critical development of a vaccine to inoculate against a global pandemic. The vaccine, once developed, was to be tested at laboratories at Dalhousie University in Halifax.

The National Research Council was to begin producing the vaccine in Canada. Bearing in mind that the NCC transferred Canadian intellectual property for use by CanSino to enable it to create the vaccine for Ebola and SARS-CoV-2. The final product was to have been delivered to Canada, but it never passed Chinese customs to arrive in Canada. Although the product was sent on to Pakistan, Russia, Mexico and Chile for trials, simply not to Canada.

"Due to lengthy delays in the shipment of the vaccine doses to Canada, the fact that CanSino’s candidate had already entered advanced testing in other countries, and the new clinical-trial data that had emerged from other jurisdictions, it was decided in late August that the opportunity to conduct clinical trials in Canada for Ad5-nCoV had passed, and the government decided to focus on more promising candidates."

National Research Council

That setback meant that Canada had no recourse to any vaccines in development and completing their trials, so at that later date in August of 2020 the Trudeau government hurriedly began making deals with U.S. and British pharmaceuticals for vaccine doses, long after most G7 countries had already made their arrangements, sending Canada to the back of the line. The result of which is that Canada has received scant few vaccine doses while other countries which either produce their own or signed contracts to keep them well supplied are inoculating their populations at a rate Canadians can only envy.

Canada, it would seem, from its then-minister of industry, 'owns' the intellectual property relating to the CanSino Biologics vaccine, but cannot access it (punishment courtesy of the CCP for having the effrontery to detain Huawei's CEO on an extradition warrant from the U.S.) because China 'owns' the vaccine now in use by the Chinese military and sent abroad elsewhere.

Canada had, it seems, also seen fit to sign the contract with CanSino that contains the proviso that: "Canada cannot claim any revenue if the vaccine proves successful". At the time of the contract signing, CanSino was trading at HK$87.45 in the Hong Kong Exchange. At the present time CanSino stock is trading at an all-time high of HK$365. Clearly, Prime Minister Justin Trudeau neglected to read former U.S.President's "Art of the Deal".

 

Faisal Sultan

@fslsltn

·

Feb 8, 2021

Clinical trial data (phase-3) of a one-dose Ad5-nCoV vaccine for Covid (Cansino Bio) received. Interim analysis by the Independent Data Monitoring Committee shows 65.7% efficacy at preventing symptomatic cases and 90.98% at preventing severe disease (multicountry analysis).

Faisal Sultan

@fslsltn

In the Pakistani subset, efficacy at preventing symptomatic cases is 74.8% & 100% at preventing severe disease. The IDMC didn't report any serious safety concerns. Data incld 30,000 participants & 101 virologically confmd COVID cases Well done Pak team for conducting this trial